The efficacy of low-dose tadalafil in patients undergoing hemodialysis with end-stage renal disease

Mustafa Suat Bolat, Ismail Özer, Onder Cinar, Ekrem Akdeniz, and Ramazan Aşçı

Department of Urology, Samsun Training and Research Hospital, Health Sciences University, Samsun, Turkey; Department of Nephrology, Samsun Training and Research Hospital, Health Sciences University, Samsun, Turkey; Department of Urology, Ondokuz Mayıs University, Samsun, Turkey

ABSTRACT

Background: Erectile dysfunction (ED) is a disorder that is frequently observed in people with chronic kidney disease who undergo hemodialysis (HD). In the context of evidence-based medicine, we aimed to investigate the effect of low-dose tadalafil on sexual function in patients undergoing HD.

Methods: The medical records of 30 males (aged 29–65 years) with end-stage renal disease (ESRD) on a HD program, and who had received 5 mg tadalafil twice weekly, were retrospectively evaluated. Changes in erectile and ejaculatory function were evaluated using the International Erectile Function Index questionnaire, the Erection Hardness Scale (EHS), and the Male Sexual Health Questionnaire (MSHQ).

Results: The mean age of the patients was 47.6 ± 10.1 years, their mean body mass index was 24.3 ± 4.2 kg/m², their mean hemoglobin was 11.9 ± 0.9 g/dL, and their mean creatinine clearance was 5.8 ± 1.1 mL/min. At the third month of treatment, 36.6% of the patients had no ED, 40% had mild ED, 10% had mild-to-moderate ED, and 13.3% had moderate ED. The mean MSHQ scores (p < .05) and the mean EHS scores (p = .001) were significantly improved. There was no significant difference between Beck’s Depression Inventory scores (p > .05), but Hamilton anxiety rate scores decreased significantly (p = .001). The quality-of-life score improved throughout the study period (p < .05).

Conclusions: Tadalafil therapy is an effective therapeutic option in patients with ESRD who undergo HD, not only for the treatment of ED, but also for ejaculatory function, with acceptable adverse effects.

Introduction

The delicate balance between detumescence and erection is maintained by harmonious interaction of the sympathetic and parasympathetic nervous systems. Alfa-1 adrenergic stimulation, which is mediated by various mediators, leads to penile smooth-muscle contraction in the flaccid phase of the penis [1]. Parasympathetic stimulation results in neurogenic nitric oxide synthase (nNOS) expression, and nNOS uses molecular oxygen and L-arginine to produce nitric oxide (NO). The NO that is produced then stimulates cyclic-GMP by protein kinase G, and finally, smooth-muscle relaxation occurs in the penis [2].

Erectile dysfunction (ED) is a disorder that is frequently observed with increasing prevalence in people with end-stage renal disease (ESRD) who undergo a hemodialysis (HD) program [3]. Several factors affect erectile function, such as low responsiveness of Leydig cells, inhibitors of Leydig cell receptors and endothelial dysfunction, which are necessary for libido, penile morphology, and penile function [4,5].

ESRD has become a global problem, and its incidence is increasing [6]. The chronic nature of the disease also leads to some other systemic problems, such as cardiovascular, skeletal, hematologic, neurogenic, immunologic and sexual disorders [7–10]. Although sexual problems are not life-threatening, they negatively affect the quality of life of people with ESRD when they occur [11].

Several studies have reported that ED prevalence is as high as 80% in ESRD people on an HD program than in the normal population [12–14]. In addition, in people with ESRD undergoing HD, sexual dysfunction occurs due to psychogenic, as well as organic, causes [15].

CONTACT Mustafa Suat Bolat mbolat@gmail.com Health Sciences University, Samsun Training and Research Hospital, Department of Urology, Baris Bulvari, Kadiköy Mahallesi, No:199, Ilkadim, 55100, Samsun, Turkey

© 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
In the present study, we aimed to investigate the effect of 5 mg tadalafil, administered twice-weekly for three months, on sexual function in people with ESRD undergoing HD, using the International Index of Erectile Function questionnaire (IIEF) [16] and the Male Sexual Health Quality questionnaire (MSHQ) [17], in the context of evidence-based medicine.

**Materials and methods**

This study was designed as a retrospective clinical trial. After obtaining approval from the Ethics Committee of Ondokuz Mayis University, Samsun, Turkey, all the patients were informed of the study for ethical reasons, and their written consents were obtained. The required number of patients was determined using a power analysis. The medical records of 30 males (aged 29–65 years) with ESRD and on HD who had previously consulted our clinic regarding sexual dysfunction, and had received 5 mg tadalafil twice weekly, were retrospectively evaluated [18]. At the beginning of the study, the patients included were assessed in terms of age, body mass index (BMI), urinary output volume (anuria, oliguria or normuria), hemoglobin, serum lipid profile (triglycerides and total cholesterol), hormonal status (total testosterone and prolactin) and creatinine clearance. A testosterone level of greater than 8.4 mmol/L and a prolactin level of less than 15 ng/mL was accepted as normal, and the diagnosis of ESRD was made by a nephrologist. Inclusion criteria were age over 18 years, an HD program for at least 6 months, and having a sexual partner, while exclusion criteria were previous genital surgery and cardiac comorbidity.

The questionnaires were interviewed face to face with patients in one session. As needed, quantitative variables were repeated throughout the study period. Changes in erectile function were evaluated using the short form of the Turkish validated IIEF [19], which consisted of six questions 1–5 and 15. Each question was scored from 1 (‘almost never’ or ‘never’) to 5 (‘almost always’ or ‘always’), and total scores were recorded. The patients were classified as having severe dysfunction (score = 0–6), moderate dysfunction (score = 7–12), mild-to-moderate dysfunction (score = 13–18), mild dysfunction (score = 19–24) and no dysfunction (score = 26–30). Erectile hardness quality was evaluated using the Erection Hardness Scale (EHS), consisting of four grades: the penis is larger but is not hard (Grade 1); hard, but not hard enough for penetration (Grade 2); hard enough for penetration, but not completely hard (Grade 3); and completely hard and fully rigid (Grade 4). Ejaculatory function was assessed using the short form of the Turkish validated MSHQ [20], consisting of four questions ranging from 0 to 5 scores. The first, second and third of these questions assess the behavior, frequency and power of the ejaculatory function (MSHQ 123) (scored from 0–15), and the fourth question assesses the ejaculatory bother (MSHQ EjD) (scored from 0–5). The higher the the sum of the first three MSHQ scores, the better the ejaculatory function; and the higher the last score, the better the ejaculatory function.

The psychological state of the patients was assessed as minimal, mild, moderate or severe depression, using the Beck’s Depression Inventory (BDI) [21,22] and the Hamilton Anxiety Rating Scale (HARS) [23,24]. The BDI consists of 21 questions, which are scored as follows: not at all; mild; moderate-2 and severe-3, respectively. A total score of 0–10 is considered normal, 11–16 = mild mood disturbance, 17–20 = borderline clinical depression, 21–30 = moderate depression, 31–40 = severe depression and ≥41 = extreme depression. The HARS consists of 17 questions, of which questions 1 and 3–9 are scored as not at all; moderate-1 and severe-3; and questions 2 and 10–17 s are scored from 0 (not at all) to 4 (severe). A score of less than 17 = mild anxiety, 18–24 = mild-to-moderate anxiety and ≥25 moderate-to-severe anxiety. Cronbach α reliability coefficients were 0.82 for IIEF; 0.79 for MSHQ, 0.87 for BDI and 0.76 for HARS.

The statistical analysis was carried out using Statistical Package for the Social Sciences for Windows software, version 21.0 (IBM, Chicago, IL) and the Shapiro–Wilk test was used to analyze the normal distribution of the quantitative data. The results are given as mean ± standard deviation, n (%) and/or median (min–max). The intragroup data were compared using the Wilcoxon signed rank test for non-normal data. Comparisons between data were performed using a paired-sample test. Pearson’s chi-square and Fisher’s exact test were used for comparisons of percentages. A p values of less than 0.05 was considered statistically significant.

**Results**

The mean age of the patients was 47.6 ± 10.1 years, their mean BMI was 24.3 ± 4.2 kg/m², and their mean hemoglobin was 11.9 ± 0.9 g/dL. The mean HD duration was 78.4 ± 27 months (24–120), the mean creatinine clearance was 5.8 ± 1.1 mL/min (4–8), and the frequency of HD was three sessions per week. The mean total serum testosterone level was 7.2 ± 1 (4.4–8.9) mmol/L, and only four patients were in the normal limits. The mean prolactin level was 5.9 ± 2.4 (3–12) ng/mL, and 11
patients were hypercholesterolemic and hypertriglyceridemic (36.6%) (Table 1).

At the beginning of tadalafil treatment, 10 of the patients had mild ED (33.3%), six had mild-to-moderate ED (20%), and 14 had moderate ED (46.6%); at the first month of treatment, 15 patients had mild ED (50%), five had mild-to-moderate ED (16.6%), and eight had moderate ED (28.6%). At the third month of treatment, 11 patients had no ED (36.6%), 12 had mild ED (40%), three had mild-to-moderate (10%), and four had moderate ED (13.3%). Overall, the ED rate was 100%, 93.3% and 66.6% at pretreatment, at the first treatment month, and after the third month of treatment, respectively (Table 2).

The mean IIEF scores at pretreatment and at the first and third month of treatment were 21 ± 4.7, 21.4 ± 4.0 and 22.6 ± 4.0, respectively. Although there was no statistically significance between the pretreatment and first month of treatment values ($p = .05$), the third month of treatment score was significantly increased compared to the pretreatment value ($p = .001$) (Table 3).

The mean MSHQ123 scores at pretreatment and at the first and third month of treatment were 9.9 ± 2.4, 10.6 ± 2.6 and 11.4 ± 0.7; the mean MSHQejD scores were 3.1 ± 0.9, 3.6 ± 0.7 and 4.0 ± 0.7, respectively. The mean MSHQ123 and mean MSHQejD scores were significantly increased at the first and third months of treatment compared to pretreatment values ($p < .05$).

The mean EHS [25] scores at pretreatment and at the first and third month of treatment were 3.3 ± 1.1, 3.6 ± 0.7 and 3.7 ± 0.7, respectively. The mean EHS scores at the first and third month of treatment were significantly increased compared to the mean pretreatment score ($p = .001$).

The mean BDI scores at pretreatment and at the first- and third-month treatment periods were 2.9 ± 5.4, 2.5 ± 2.2 and 2.9 ± 2.3, respectively, but there was no statistically significant difference ($p > .05$). Four of the patients had borderline clinical depression (13.3%), and one had moderate depression (3.3%) throughout the treatment period. The mean pretreatment, and the

Table 1. Demographic characteristics of the patients.

| No. of the patients | 30 |
|---------------------|----|
| Age (years), (mean ± SD) | 47.6 ± 10.1 |
| BMIa (kg/m²) | 24.3 ± 4.2 |
| Hbb (g/dL) | 11.9 ± 0.9 |
| Total cholesterol (mg/dL) | 202.6 ± 6 |
| Triglyceride (mg/dL) | 190.3 ± 36.2 |
| Total testosterone mmol/L | 7.2 ± 1.0 |
| Prolactine ng/mL | 5.9 ± 2.4 |
| Hemodialysis duration (months), (mean ± SD), (min–max) | 78.4 ± 27 (24–120) |
| Hemodialysis frequency (n/week) | 3 |
| Creatinine clearance (mL/min), (mean ± SD), (min–max) | 5.8 ± 1.1 (4–8) |
| Comorbidity (n, %) | |
| Diabetes mellitus | 19 (63.3) |
| Hypertension | 6 (20.0) |
| Polycystic kidney | 1 (3.4) |
| Idiopathic | 4 (13.3) |

aBMI: body mass index.

bHb: hemoglobin.

Table 2. Erectile dysfunction classification of the patients.

| Pretreatment | First month of treatment | Third month of treatment |
|--------------|-------------------------|-------------------------|
| Severe ED (0–6) | 0 | 0 | 0 |
| Moderate ED (7–12) | 14 (46.6) | 8 (28.6) | 4 (13.3) |
| Mild to moderate ED (13–18) | 6 (20.0) | 5 (16.6) | 3 (10.0) |
| Mild ED (19–25) | 10 (33.3) | 15 (50.0) | 12 (40.0) |
| No ED (>26) | 0 | 2 (6.6) | 11 (36.6) |
| Overall ED | 30 (100) | 28 (93.4) | 23 (76.6) |

Table 3. Findings of sexual, psychogenic, and quality of life through tadalafil treatment.

| Variable | Pretreatment | First month of treatment | Third month of treatment | Difference between pretreatment and third month (%) |
|----------|--------------|-------------------------|-------------------------|---------------------------------------------------|
| IIEF² (1–5,15) | 21 ± 4.7 | 21.4 ± 4.0 | 22.6 ± 4.0 | +7.6 |
| MSHQ123b | 9.9 ± 2.4 | 10.6 ± 2.6 | 11.4 ± 0.7 | +14.1 |
| MSHQ EjD | 3.1 ± 0.9 | 3.6 ± 0.7 | 4.0 ± 0.7 | +31.7 |
| EHSd | 3.3 ± 1.1 | 3.6 ± 0.7 | 3.7 ± 0.7 | +12.1 |
| Beck’s score | 2.9 ± 5.4 | 2.5 ± 2.2 | 2.9 ± 2.3 | −8.8 |
| Hamilton score | 19.3 ± 4.2 | 12.5 ± 3.1 | 10.5 ± 2.6 | −45.6 |
| QoL² score | 3.4 ± 0.7 | 3.1 ± 0.5 | 2.8 ± 0.4 | +17.6 |

²Short form of International Index of Erectile Function score.

bMSHQ 123 defines ejaculatory function.

²MSHQejD defines ejaculatory dysfunction.

²Erection Hardness Scale.

²QoL: quality of life score.

584 M. S. BOLAT ET AL.
first- and third-month treatment HARS scores were 19.3 ± 4.2, 12.5 ± 3.1 and 10.5 ± 2.6, respectively. The first month and third month of treatment mean HARS scores were statistically decreased compared to the mean pre-treatment score (p = .001) (Table 3). The quality-of-life score improved at the end of the first month (p = .04) and third month (p = .02) of treatment.

Discussion

Prior to the phosphodiesterase type-5 (PDE5) inhibitor era, ED treatment consisted of conservative options, including dialysis, correction of anemia using erythropoietin, testosterone supplementation, vacuum devices, penile or intraurethral vasoactive injections or surgical procedures, such as penile prosthesis and vascular surgery [26]. Although tadalafil is rapidly absorbed with a median 2 h of T\text{max} in healthy men, and metabolism is completed in the liver, almost 36% of an oral dose is excreted in the urine [27]. To date, only a limited number of studies have investigated the effects of low-dose tadalafil in people with ESRD and on HD, although numerous studies have reported the effects of different sildenafil doses in such individuals. Chen et al. reported that sildenafil therapy increased the IIEF score by a minimum of 10 points in 80% of patients [28], while Jacques et al. found that only two of 15 patients (13.3%) were satisfied with different doses of sildenafil treatment [29]. Our study revealed that low-dose tadalafil administration twice-weekly for 3 weeks resulted in significant improvement in the total mean IIEF scores and ejaculatory function scores, irrespective of etiology. Of the 30 patients, 11 (36.6%) had no ED at the end of the third month of therapy.

Many studies have reported that patients have discontinued tadalafil treatment due to adverse effects, or the lack of drug efficacy. Although none of the patients in the present study stopped the therapy due to minor side effects, 28 (93.3%) stated that they would not be able to continue the therapy for a long time because tadalafil was not covered by their insurance. It has previously been reported that diabetes mellitus and hypertension are the comorbidities most commonly associated with ED in HD patients [30]. Although the use of more than one antihypertensive agent has been reported in the treatment of hypertension for greater risk of ED, only six of the 30 patients (20%) were taking an alpha blocker for hypertension [31]. In the present study, we found no relationship between sexual dysfunction and hormonal and metabolic states, which was in accordance with previous studies [32].

Of the patients in the present study, 26 were hypandrogenic due to abovementioned reasons, in accordance with previous studies, but none were hyperprolactinemic [33]. Another factor that alters erectile function is endothelial dysfunction [34]. It is expected that the more endothelial dysfunction occurs, the more likely it is that NO production decreases. Kensinger et al. showed that the increased amount of fibroblast growth factor-23 that is observed in ESRF was associated with endothelial dysfunction 2 years after renal transplantation. That suggested that the progressive endothelial dysfunction process continues in people with ESRD [35]. It has been shown that tadalafil decreases arterial stiffness and improves left ventricular diastolic function, even in patients with no cardiovascular or atherosclerotic diseases [36]. In contrast with this report, Pelliccione et al. claimed that tadalafil had only a modest effect on endothelial recovery [37]. Our results suggested that optimum effort must be made to guard against other cardiovascular risk factors, such as hypertension and hyperlipidemia, which promote endothelial dysfunction, in addition to using tadalafil treatment in patients with ESRD.

A limited number of previous studies have investigated ejaculatory disorders in ESRD. In those studies, ejaculation disorders were reported in 28–51.5% of HD patients [38–42]. Ejaculatory dysfunction is a common comorbidity with the prevalence of 25–40% [41]. In a review by Paduch et al., 57.8% of the 12,130 participants had abnormal ejaculation, and severity of ED was associated with poorer ejaculatory function [42]. Corona et al. reported that testosterone had a central and a peripheral role in ejaculatory reflex; according to widely accepted opinion, ejaculatory dysfunction might be mitigated following primary treatment of ED with PDE5 inhibitors [43]. The results of the present study revealed that tadalafil improved the mean MSHQ123 and MSHQ EjD scores throughout the follow-up period, which supports that hypothesis.

Psychogenic causes are another etiological reason in ESRD patients compared to age-matched counterparts without renal failure [44]. According to the World Health Organization, the prevalence of depression is approximately 16% [45]. Chronic illnesses contribute to this high prevalence, because psychosocial status is negatively affected, and patients are at risk of physical restrictions throughout their life. It has been shown that ED and stress negatively interact with each other and could lead to psychosocial problems [46]. Melnik et al. reported that psychotherapy plus PDE-5 inhibition resulted in significant improvement compared to PDE-5 inhibition alone, [47] while Baek et al. reported that tadalafil decreased depressive symptoms by affecting apoptotic neuronal cell death suppression in rats [48].
In the present study, none of the patients showed depression according to the BDI which was stable throughout the 3-month period. In a review, Chilcot et al. reported that the prevalence of depression was 8.1–71.4% in different studies [49]. However, the mean HARS score decreased by 45.6% with tadalafil treatment. In addition to erectile improvement, lack of alterations in testosterone, hemoglobin, and lipid profile suggested that the positive impact of tadalafil on anxiety was associated with higher sexual quality and satisfaction [50,51].

Limitations of this study
The short duration of therapy due to treatment costs, the low number of patients studied, and an absence of evaluation of the patients' partners.

Conclusions
Tadalafil therapy is an effective therapeutic option in people with ESRD who undergo HD. Tadalafil 5 mg twice weekly not only improved ED, but also improved ejaculatory function, with acceptable adverse effects. Correctable conditions, such as hypertension and hyperlipidemia, which promote endothelial dysfunction, may influence treatment success rate, and a systematic approach is obligatory for improved outcomes.

Disclosure statement
Authors declare no conflict of interest and the results presented in this paper have not been published previously in whole or part, except in abstract format.

Authors declare they did not receive any funding or support for the present study and that there are no potential conflicts of interest related with it.

References
[1] Angulo J, Cuevas P, La Fuente JM, et al. Regulation of human penile smooth muscle tone by prostanoid receptors. Br J Pharmacol. 2002;136:23–30.
[2] Hedlund P, Alm P, Andersson KE. NO synthase in cholinergic nerves and NO-induced relaxation in the rat isolated corpus cavernosum. Br J Pharmacol. 1999;127:349–360.
[3] Nassir A. Erectile dysfunction risk factors for patients entering dialysis programme. Andrologia. 2010;42:41–47.
[4] Stewart-Bentley M, Gans D, Horton R. Regulation of gonadal function in uremia. Metab Clin Exp. 1974; 23:1065–1072.
[5] Dunkel L, Raivio T, Laine J, et al. Circulating luteinizing hormone receptor inhibitor(s) in boys with chronic renal failure. Kidney Int. 1997;51:777–784.
[6] Messina LE, Claro JA, Archimedes N, et al. Erectile dysfunction in patients with chronic renal failure. Int Braz J Urol. 2007;33:673–678.
[7] Nasuto M, Pansini V, Cortet B, et al. Renal failure: a modern semiology for an old disease. Semin Musculoskelet Radiol. 2016;20:353–368.
[8] Mavraganitas TA, Charytan DM. Cardiovascular complications in chronic dialysis patients. Curr Opin Nephrol Hypertens. 2016;25:536–544.
[9] Coskun Y, Paydas S, Balal M, et al. Bone disease and serum fibroblast growth factor-23 levels in renal transplant recipients. Transplant. Proc. 2016;48:2040–2045.
[10] Gorsane I, Amri N, Younsi F, et al. Erectile dysfunction in hemodialysis patients. Saudi J Kidney Dis Transpl. 2016;27:23–28.
[11] Weisbord SD, Mor MK, Green JA, et al. Comparison of symptom management strategies for pain, erectile dysfunction, and depression in patients receiving chronic hemodialysis: a cluster-randomized effectiveness trial. Clin J Am Soc Nephrol. 2013;8:90–99.
[12] Mekki MO, El Hassan KA, El Mahdi EM, et al. Prevalence and associated risk factors of male erectile dysfunction among patients on hemodialysis and kidney transplant recipients: a cross-sectional survey from Sudan. Saudi J Kidney Dis Transpl. 2013;24:500–506.
[13] Makarem AR, Karami MY, Zekavat OR. Erectile dysfunction among hemodialysis patients. Int Urol Nephrol. 2011;43:117–123.
[14] Rosas S, Joffe M, Franklin E, et al. Prevalence and determinants of erectile dysfunction in hemodialysis patients. Kidney Int. 2001;59:2259–2266.
[15] Fernandes GV, dos Santos RR, Soares W, et al. The impact of erectile dysfunction on the quality of life of men undergoing hemodialysis and its association with depression. J Sex Med. 2010;7:4003–4010.
[16] Rosen CR, Riley A, Wagner G, et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49:822–830.
[17] Rosen RC, Catania JA, Althof SE, et al. Development and validation of four-item version of Male Sexual Health Questionnaire to assess ejaculatory dysfunction. Urology. 2007;69:805–809.
[18] (16)CIALIS® (tadalafil). Full Prescribing Information. Indianapolis (IN): Lilly ICOS LLC; 2009.
[19] Turunç T, Deveci S, Güvel S, et al. The assessment of Turkish validation with 5 question version of International Index of Erectile Function (IIEF-5). Turkish J Urol. 2007;33:45–49.
[20] Kendirci M, Asci R, Yaman O, et al. Prevalence of male pelvic dysfunction: results from the Turkish society of andrology male sexual health study group. Andrology. 2014;2:219–224.
[21] Beck AT, Steer RA, Brown GK. Manual for the Beck depression inventory-II. San Antonio (TX): Psychological Corporation.
[22] Aydemir Ö, Koroğlu E. Psikiyatride kullanılan klinik örnekler. Hekimler Ya Despite Birlılı; 2009. ISBN: 9789753001250;93–335.
[23] Maier W, Buller R, Philipp M, et al. The Hamilton Anxiety Scale: reliability, validity and sensitivity to
change in anxiety and depressive disorders. J Affect Disord. 1988;14:61–68.

[24] Yazıcı MK, Demir B, Tanrıverdi N, et al. Hamilton anksiyete değerlendirme ölçeği, değerlendirmeçilere arası güvenilirlik ve geçerlilik çalışması. Turkish J Psychiatry. 1998;11:114–117.

[25] Parisot J, Yiu R, Salomon L, et al. Erection hardness score for the evaluation of erectile dysfunction: further psychometric assessment in patients treated by intracavernous prostaglandins injections after radical prostatectomy. J Sex Med. 2014;11:2109–2118.

[26] Barry JM. Treating erectile dysfunction in renal transplant recipients. Drugs. 2007;67:975–983.

[27] Fougue ST, Patterson BE, Bedding AW, et al. Pharmacokinetics in healthy subjects. Br J Clin Pharmacol. 2007;63:24–35.

[28] Chen J, Mabjeesh NJ, Greenstein A, et al. Clinical efficacy of sildenafil in patients on chronic dialysis. J Urol. 2001;165:819–821.

[29] Jacques J, Abrairs C. Quality-of-life issues in hemodialysis: case studies on the use of sildenafil for erectile dysfunction. Dial Transplant. 1999;28:519–524.

[30] El-Bahnasawy MS, El-Assmy A, El-Sawy E, et al. Critical factors influencing erectile function after renal transplantation. Int J Impot Res. 2004;16:521–526.

[31] Abdel-Hamid IA, Eraky I, Fouda MA, et al. Role of penile vascular insufficiency in erectile dysfunction in renal transplant recipients. Int J Impot Res. 2002;14:32–37.

[32] (23)Rebollo P, Ortega F, Valdes C, et al. Factors associated with erectile dysfunction in male kidney transplant recipients. Int J Impot Res. 2003;15:433–438.

[33] Maggi M, Buvat J, Corona G, et al. Review hormonal causes of male sexual dysfunctions and their management (hyperprolactinemia, thyroid disorders, GH disorders, and DHEA. J Sex Med. 2013;10:661–677.

[34] Yilmaz MI, Stenvinkel P, Sonmez A, et al. Vascular health, systemic inflammation and progressive reduction in kidney function: clinical determinants and impact on cardiovascular outcomes. Nephrol Dial Transplant. 2011;26:3537–3543.

[35] Kensinger C, Bian A, Fairchild M, et al. Long term evolution of endothelial function during kidney transplantation. BMC Nephrol. 2016;17:160.

[36] Özdağakgölu O, Güllü S, Sag S, et al. Evaluation of arterial stiffness and cardiac functions in patients with vascular erectile dysfunction: acute effects of phosphodiesterase-5 inhibitor tadalafil. Int J Impot Res. 2017;29:96–100.

[37] Pelliccione F, D’Angeli A, D’Andrea S, et al. Tadalafil treatment had a modest effect on endothelial cell damage and repair ability markers in men with erectile dysfunction and vascular risk. Asian J Androl. 2014;16:290–294.

[38] Zamd M, Gharbi MB, Ramdani B, et al. Sexual dysfunction in male patients undergoing hemodialysis in Morocco. Saudi J Kidney Dis Transpl. 2005;16:33–39.

[39] Suzuki N, Kumamoto Y. [Study of sexual function in male hemodialysis patients – a sexual function survey using a questionnaire]. Nihon Hinyokika Gakkai Zasshi. 1995;86:1088–1097.

[40] (31)Lew-Starowicz M, Gellert R. The sexuality and quality of life of hemodialyzed patients-ASED multicenter study. J Sex Med. 2009;6:1062–1071.

[41] Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review article. J Clin Psychopharmacol. 1999;19:67–85.

[42] Paduch DA, Bolyakov A, Beardsworth A, et al. Factors associated with ejaculatory and orgasmic dysfunction in men with erectile dysfunction: analysis of clinical trials involving the phosphodiesterase type 5 inhibitor tadalafil. BJU Int. 2012;109:1060–1067.

[43] Corona G, Jannini EA, Lotti F. Premature and delayed ejaculation: two ends of a single continuum influenced by hormonal milieu. Int J Androl. 2011;34:41–48.

[44] Elhadj FK, Sidy MSck, Mouhamadou MC, et al. Erectile dysfunction in chronic hemodialysis patients in Dakar: a cross-sectional study in 2012. Nephrourol Mon. 2014;6:e21138.

[45] Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095–3105.

[46] Kalaitzidou I, Venetikou MS, Konstadinidis K, et al. Stress management and erectile dysfunction: a pilot comparative study. Andrologia. 2014;46:698–702.

[47] Melnik T, Soares BG, Nascimento AG. Psychosocial interventions for erectile dysfunction. Cochrane Database Syst Rev. 2007;3:CD004825.

[48] Baek SB, Bahn G, Moon SJ, et al. The phosphodiesterase type 5 inhibitor, tadalafil, improves depressive symptoms, ameliorates memory impairment, as well as suppresses apoptosis and enhances cell proliferation in the hippocampus of maternal-separated rat pups. Neurosci Lett. 2011;488:26–30.

[49] Chilcot J, Wellsted D, Da Silva-Gane M, et al. Depression on dialysis. Nephron Clin Pract. 2008;108:c256.

[50] Seftel AD, Rosen RC, Hayes RP, et al. Effect of once-daily tadalafil on confidence and perceived difficulty in performing sexual intercourse in men who were incomplete responders to as-needed PDE5 inhibitor treatment. Int J Clin Pract. 2014;68:841–849.

[51] Tsujimura A, Kiuchi H, Soda T, et al. Sexual life of Japanese patients with erectile dysfunction taking phosphodiesterase type 5 inhibitors: an Internet survey using the Psychological and Interpersonal Relationship Scales-Short Form questionnaire. Int J Urol. 2014;21:821–825.